Barclays PLC Neurocrine Biosciences Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Barclays PLC holds 181,591 shares of NBIX stock, worth $25.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

181,591

Previous 181,591 -0.0%

Holding current value

$25.6 Million

Previous $20.9 Million -0.0%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$114.58 - $153.15 $2.2 Million - $2.94 Million	19,202 Added 11.82%	181,591 $20.9 Million
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $12.4 Million - $13.6 Million	-94,850 Reduced 36.87%	162,389 $22.4 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $3.27 Million - $3.6 Million	25,071 Added 10.8%	257,239 $35.5 Million
Q4 2023 Feb 15, 2024	BUY	$106.07 - $132.76 $5.72 Million - $7.16 Million	53,905 Added 30.24%	232,168 $30.6 Million
Q3 2023 Nov 07, 2023	SELL	$94.02 - $117.1 $1.53 Million - $1.9 Million	-16,259 Reduced 8.36%	178,263 $20.1 Million
Q2 2023 Aug 03, 2023	SELL	$89.53 - $104.87 $4.79 Million - $5.61 Million	-53,472 Reduced 21.56%	194,522 $18.3 Million
Q1 2023 May 04, 2023	BUY	$94.11 - $123.02 $8.68 Million - $11.3 Million	92,208 Added 59.19%	247,994 $25.1 Million
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $980,009 - $1.17 Million	9,183 Added 6.26%	155,786 $18.6 Million
Q3 2022 Nov 03, 2022	BUY	$92.03 - $107.81 $2.56 Million - $3 Million	27,837 Added 23.44%	146,603 $15.6 Million
Q2 2022 Aug 12, 2022	BUY	$75.79 - $100.07 $307,328 - $405,783	4,055 Added 3.53%	118,766 $11.6 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $1.28 Million - $1.68 Million	-17,676 Reduced 13.35%	114,711 $10.8 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $1.83 Million - $2.44 Million	-23,000 Reduced 14.8%	132,387 $11.3 Million
Q3 2021 Nov 09, 2021	SELL	$86.18 - $99.03 $4.1 Million - $4.72 Million	-47,617 Reduced 23.46%	155,387 $14.9 Million
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $11.4 Million - $13 Million	127,576 Added 169.14%	203,004 $19.8 Million
Q1 2021 May 13, 2021	BUY	$87.57 - $119.4 $3.2 Million - $4.37 Million	36,573 Added 94.13%	75,428 $7.34 Million
Q4 2020 Feb 11, 2021	SELL	$86.91 - $108.33 $2.88 Million - $3.59 Million	-33,124 Reduced 46.02%	38,855 $3.72 Million
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $2.73 Million - $3.84 Million	28,431 Added 65.29%	71,979 $6.92 Million
Q2 2020 Aug 12, 2020	BUY	$85.09 - $130.36 $1.07 Million - $1.64 Million	12,558 Added 40.52%	43,548 $5.31 Million
Q1 2020 May 13, 2020	SELL	$75.11 - $113.76 $3.01 Million - $4.55 Million	-40,014 Reduced 56.35%	30,990 $2.68 Million
Q4 2019 Feb 10, 2020	BUY	$86.8 - $118.57 $1.61 Million - $2.19 Million	18,501 Added 35.24%	71,004 $7.63 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $2.73 Million - $3.3 Million	-32,557 Reduced 38.28%	52,503 $4.73 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $131,332 - $165,928	1,818 Added 2.18%	85,060 $7.18 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $422,167 - $557,509	6,091 Added 7.89%	83,242 $7.33 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $3.62 Million - $6.59 Million	52,969 Added 219.04%	77,151 $5.51 Million
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $173,831 - $221,244	1,758 Added 7.84%	24,182 $2.97 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $1.2 Million - $1.69 Million	-15,989 Reduced 41.62%	22,424 $2.2 Million
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $400,191 - $487,475	5,274 Added 15.91%	38,413 $3.19 Million
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $19,724 - $26,147	-337 Reduced 1.01%	33,139 $2.57 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $1.61 Million - $2.05 Million	33,476	33,476 $2.05 Million

Others Institutions Holding NBIX

# of Institutions

627

Shares Held

94M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account